ESMO: AstraZeneca, Merck tout Lynparza's 'clinically meaningful' ovarian cancer survival edge but lose one in prostate cancer
9th September 2022 Uncategorised 0ESMO: AstraZeneca, Merck tout Lynparza’s ‘clinically meaningful’ ovarian cancer survival edge but lose one in prostate cancer aliu Fri, 09/09/2022 – 10:58 More: ESMO: AstraZeneca, Merck tout Lynparza's 'clinically meaningful' ovarian cancer survival edge but lose one in prostate cancer
read more